Literature DB >> 11959568

In vitro and in vivo activities of posaconazole against Coccidioides immitis.

Gloria M González1, Rolando Tijerina, Laura K Najvar, Rosie Bocanegra, Michael Rinaldi, David Loebenberg, John R Graybill.   

Abstract

Posaconazole (SCH 56592) was tested against 25 strains of Coccidioides immitis to determine their in vitro susceptibilities. The geometric mean 48-h MIC of posaconazole (POSA) was 0.5 microg/ml, the MIC range was 0.25 to 1 microg/ml, and the MIC at which 50% of the isolates tested are inhibited (MIC50) and the MIC90 were 0.5 and 1 microg/ml, respectively. The geometric mean 48-h MIC of itraconazole (ITRA) was 0.23 microg/ml, the MIC range was 0.125 to 0.5 microg/ml, and the MIC50 and MIC90 were both 0.25 microg/ml. Two strains of C. immitis were selected for in vivo studies on the basis of the POSA 48-h MICs for the isolates. POSA orally administered at 0.01, 0.1, 0.5, 1, 5, and 10 mg/kg of body weight/day was compared with ITRA administered at 10 and 30 mg/kg three times a day. The spleens and livers of mice that died or survived to day 50 were removed to measure the fungal burdens. Mice had >or=90% survival when they were treated with >or=0.5 mg of POSA per kg or 30 mg of ITRA per kg. Cultures of whole spleens and livers from mice treated with 10 mg of POSA per kg showed >or=70% sterilization. No sterilization of whole spleens and livers from mice treated with ITRA was seen. POSA displayed potent in vivo activity against the two strains of C. immitis tested.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959568      PMCID: PMC127157          DOI: 10.1128/AAC.46.5.1352-1356.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials.

Authors:  H A Gallis
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

2.  In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  A A Nomeir; P Kumari; M J Hilbert; S Gupta; D Loebenberg; A Cacciapuoti; R Hare; G H Miller; C C Lin; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Use of potato flakes agar in clinical mycology.

Authors:  M G Rinaldi
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

6.  Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group.

Authors:  J R Graybill; D A Stevens; J N Galgiani; W E Dismukes; G A Cloud
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

Review 7.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

8.  Activity of cilofungin against Coccidioides immitis: differential in vitro effects on mycelia and spherules correlated with in vivo studies.

Authors:  J N Galgiani; S H Sun; K V Clemons; D A Stevens
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

9.  Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group.

Authors:  A Catanzaro; J N Galgiani; B E Levine; P K Sharkey-Mathis; J Fierer; D A Stevens; S W Chapman; G Cloud
Journal:  Am J Med       Date:  1995-03       Impact factor: 4.965

10.  Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis.

Authors:  K V Clemons; L H Hanson; A M Perlman; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more
  21 in total

1.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Monika Martinho; Bhavna Kantesaria; Lisa Pedicone
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

Review 4.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Disposition of posaconazole following single-dose oral administration in healthy subjects.

Authors:  Philip Krieter; Brian Flannery; Timothy Musick; Mark Gohdes; Monika Martinho; Rachel Courtney
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.

Authors:  Rachel Courtney; David Wexler; Elaine Radwanski; Josephine Lim; Mark Laughlin
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.